Evaluating the effectiveness and utility of a novel culturally

Evaluating the effectiveness and utility of a novel culturally-adapted telemonitoring system in bettering the glycaemic management of Asians with type-2 diabetes mellitus: a blended technique research protocol

Background: Common supervision of sufferers with type-2 diabetes mellitus (T2DM) by healthcare suppliers is crucial to optimise their glycaemic management however is difficult to attain in present care fashions. Telemonitoring is postulated to bridge this hole by leveraging on internet-of-things and mobile-health expertise. This research goals to find out the effectiveness of a novel telemonitoring system (OPTIMUM) in bettering the glycaemic management of sufferers with T2DM in contrast with commonplace of care alone.

Strategies: This mixed-method research contains an preliminary randomised managed trial involving 330 Asian adults with T2DM, aged 26-65 years outdated with an HbA1c of seven.5-10%, with 115 within the intervention and management arms every. These within the intervention arm will use standardised Bluetooth-enabled gadgets to transmit their capillary glucose, blood strain and weight measurements to the OPTIMUM system.

Main care physicians and nurses will remotely supervise them in accordance with an embedded administration algorithm for six months, together with tele-education by way of weekly movies over Eight weeks and asynchronous tele-consultation if irregular or absent parameters are detected. Sufferers in each arms will probably be assessed at baseline, 6, 12 and 24 months post-recruitment.

The first end result will probably be their HbA1c distinction between each arms at baseline and 6 months. Blood strain and weight management; high quality of life, medicine adherence, confidence in self-management, diabetic literacy and associated misery and healthcare utilisation utilizing validated questionnaires; and incident retinal, renal, cardiac and cerebrovascular problems will probably be in contrast between the 2 arms as secondary outcomes at stipulated time-points. Intervention arm sufferers will probably be interviewed utilizing qualitative analysis strategies to grasp their expertise, acceptance and perceived usefulness of the OPTIMUM system.

Dialogue: General, this research seeks to judge the effectiveness of cultural-adapted telemonitoring system in bettering glycaemic management of Asians with type-2 diabetes mellitus in comparison with commonplace of care. The outcomes of this trial will higher inform coverage makers in adopting telemedicine for inhabitants well being administration.

insuline-medical
insuline-medical

RRAD antibody

70R-5797 50 ug
EUR 467
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD antibody

70R-5798 50 ug
EUR 467
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD Antibody

37229-100ul 100ul
EUR 252

RRAD Antibody

1-CSB-PA003910
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000

RRAD Antibody

1-CSB-PA779820
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

RRAD Antibody

1-CSB-PA248209
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100

RRAD Antibody

CSB-PA233809-
EUR 335
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

RRAD Antibody

CSB-PA233809-100ul 100ul
EUR 316
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

Rrad/ Rat Rrad ELISA Kit

ELI-14921r 96 Tests
EUR 886

RRAD Conjugated Antibody

C37229 100ul
EUR 397

Polyclonal RRAD Antibody

APR05556G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications:

RRAD siRNA

20-abx932133
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

RRAD Blocking Peptide

20-abx063234
  • EUR 272.00
  • EUR 411.00
  • 1 mg
  • 5 mg
  • Shipped within 5-10 working days.

RRAD Blocking Peptide

33R-4793 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797

RRAD Blocking Peptide

33R-10070 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798

Anti-RRAD (aa36-48) antibody

STJ72757 100 µg
EUR 359

RRAD ELISA KIT|Human

EF005507 96 Tests
EUR 689

Human RRAD shRNA Plasmid

20-abx954199
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

RRAD Recombinant Protein (Human)

RP095493 100 ug Ask for price

RRAD Recombinant Protein (Rat)

RP226925 100 ug Ask for price

RRAD Recombinant Protein (Mouse)

RP169340 100 ug Ask for price

GTP-Binding Protein RAD (RRAD) Antibody

20-abx008742
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul
  • Shipped within 5-10 working days.

GTP-binding protein RAD (RRAD) Antibody

20-abx324872
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug
  • Shipped within 5-10 working days.

GTP-binding protein RAD (RRAD) Antibody

20-abx214509
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

GTP-binding protein RAD (RRAD) Antibody

abx332370-100ul 100 ul
EUR 425
  • Shipped within 5-10 working days.

GTP-Binding Protein RAD (RRAD) Antibody

abx432011-200ul 200 ul
EUR 384
  • Shipped within 1-3 working days.

GTP-binding protein RAD (RRAD) Antibody

20-abx241706
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Polyclonal RRAD (aa36-48) Antibody (internal region)

APG00807G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications:

RRAD ORF Vector (Human) (pORF)

ORF031832 1.0 ug DNA
EUR 405

Rrad ORF Vector (Mouse) (pORF)

ORF056448 1.0 ug DNA
EUR 506

Rrad ORF Vector (Rat) (pORF)

ORF075643 1.0 ug DNA
EUR 506

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx122938-100ug 100 ug
EUR 391
  • Shipped within 5-10 working days.

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx237237-100ug 100 ug
EUR 551
  • Shipped within 5-12 working days.

RRAD sgRNA CRISPR Lentivector set (Human)

K2069901 3 x 1.0 ug
EUR 339

Rrad sgRNA CRISPR Lentivector set (Mouse)

K3480701 3 x 1.0 ug
EUR 339

Rrad sgRNA CRISPR Lentivector set (Rat)

K7052701 3 x 1.0 ug
EUR 339

RRAD sgRNA CRISPR Lentivector (Human) (Target 1)

K2069902 1.0 ug DNA
EUR 154

RRAD sgRNA CRISPR Lentivector (Human) (Target 2)

K2069903 1.0 ug DNA
EUR 154

RRAD sgRNA CRISPR Lentivector (Human) (Target 3)

K2069904 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3480702 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3480703 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3480704 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Rat) (Target 1)

K7052702 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Rat) (Target 2)

K7052703 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Rat) (Target 3)

K7052704 1.0 ug DNA
EUR 154

RRAD Protein Vector (Human) (pPB-C-His)

PV127326 500 ng
EUR 552

RRAD Protein Vector (Human) (pPB-N-His)

PV127327 500 ng
EUR 552

RRAD Protein Vector (Human) (pPM-C-HA)

PV127328 500 ng
EUR 552

RRAD Protein Vector (Human) (pPM-C-His)

PV127329 500 ng
EUR 552

RRAD Protein Vector (Rat) (pPB-C-His)

PV302570 500 ng
EUR 603

RRAD Protein Vector (Rat) (pPB-N-His)

PV302571 500 ng
EUR 603

RRAD Protein Vector (Rat) (pPM-C-HA)

PV302572 500 ng
EUR 603

RRAD Protein Vector (Rat) (pPM-C-His)

PV302573 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPB-C-His)

PV225790 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPB-N-His)

PV225791 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPM-C-HA)

PV225792 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPM-C-His)

PV225793 500 ng
EUR 603

Rrad 3'UTR GFP Stable Cell Line

TU168183 1.0 ml Ask for price

RRAD 3'UTR Luciferase Stable Cell Line

TU022380 1.0 ml
EUR 1394

Rrad 3'UTR Luciferase Stable Cell Line

TU118183 1.0 ml Ask for price

RRAD 3'UTR GFP Stable Cell Line

TU072380 1.0 ml
EUR 1394

Rrad 3'UTR Luciferase Stable Cell Line

TU219725 1.0 ml Ask for price

Rrad 3'UTR GFP Stable Cell Line

TU269725 1.0 ml Ask for price

Mouse GTP- binding protein RAD, Rrad ELISA KIT

ELI-14089m 96 Tests
EUR 865

Human GTP- binding protein RAD, RRAD ELISA KIT

ELI-35549h 96 Tests
EUR 824

Human GTP-binding protein RAD (RRAD) ELISA Kit

abx385354-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

Mouse GTP-binding protein RAD (RRAD) ELISA Kit

abx390415-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

Rat GTP-binding protein RAD (RRAD) ELISA Kit

abx391893-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV658369 1.0 ug DNA
EUR 514

RRAD Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV658373 1.0 ug DNA
EUR 514

RRAD Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV658374 1.0 ug DNA
EUR 514

Rrad ELISA Kit| Rat GTP-binding protein RAD ELISA Kit

EF019253 96 Tests
EUR 689

Rrad ELISA Kit| Mouse GTP-binding protein RAD ELISA Kit

EF016057 96 Tests
EUR 689

Human RRAD And GEM Like GTPase 2 (REM2) ELISA Kit

abx382769-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K2069905 3 x 1.0 ug
EUR 376

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3480705 3 x 1.0 ug
EUR 376

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K7052705 3 x 1.0 ug
EUR 376

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K2069906 1.0 ug DNA
EUR 167

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K2069907 1.0 ug DNA
EUR 167

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K2069908 1.0 ug DNA
EUR 167

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3480706 1.0 ug DNA
EUR 167

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3480707 1.0 ug DNA
EUR 167

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3480708 1.0 ug DNA
EUR 167

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV658370 1.0 ug DNA
EUR 514

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV658371 1.0 ug DNA
EUR 572

RRAD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV658372 1.0 ug DNA
EUR 572

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K7052706 1.0 ug DNA
EUR 167

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K7052707 1.0 ug DNA
EUR 167

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K7052708 1.0 ug DNA
EUR 167

H2B Antibody Antibody

AF4659 200ul
EUR 376
Description: H2B Antibody Antibody detects endogenous levels of H2B.

CD11b Antibody Antibody

ABD2911 100 ug
EUR 438

anti- Antibody^Polyclonal antibody control antibody

LSMab09882 100 ug
EUR 438

Ly1 Antibody Reactive (LYAR) Antibody

20-abx123734
  • EUR 411.00
  • EUR 592.00
  • 100 ul
  • 200 ul
  • Shipped within 5-10 working days.

Anti-Glycolipid Antibody (AGA) Antibody

abx036399-100ug 100 ug
EUR 391
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-400ul 400 ul
EUR 523
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-80l 80 µl
EUR 286
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx008109
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul
  • Shipped within 5-10 working days.

Anti-Glycolipid Antibody (AGA) Antibody

20-abx004855
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx014333
  • EUR 314.00
  • EUR 98.00
  • EUR 398.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx324434
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319900
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319901
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319905
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319913
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

20-abx311665
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody

abx234901-100ug 100 ug
EUR 551
  • Shipped within 5-12 working days.

Anti-Glycolipid Antibody (AGA) Antibody

abx230204-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Anti-Anti-SEPT2 Antibody antibody

STJ28365 100 µl
EUR 277

Anti-Anti-SEPT7 Antibody antibody

STJ28963 100 µl
EUR 277
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT6 antibody antibody

STJ11100949 100 µl
EUR 277
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined.

Anti-Anti-SEPT2 Antibody antibody

STJ25475 100 µl
EUR 277

Anti-Anti-SEPT5 Antibody antibody

STJ25477 100 µl
EUR 277
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-SEPT8 Antibody antibody

STJ25479 100 µl
EUR 277
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-SEPT9 Antibody antibody

STJ111369 100 µl
EUR 277
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.

Anti-Anti-SEPT11 Antibody antibody

STJ111530 100 µl
EUR 277

Anti-Anti-SEPT4 Antibody antibody

STJ112276 100 µl
EUR 277
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer.

Anti-Anti-MARCH9 Antibody antibody

STJ112609 100 µl
EUR 277

Anti-Anti-SEPT11 Antibody antibody

STJ113941 100 µl
EUR 277

Anti-Anti-SEPT11 Antibody antibody

STJ114081 100 µl
EUR 277

Anti-Anti-SEPT5 Antibody antibody

STJ114819 100 µl
EUR 277
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-MARCH8 Antibody antibody

STJ114828 100 µl
EUR 277

Anti-Anti-MARCH6 Antibody antibody

STJ118549 100 µl
EUR 277

Anti-Anti-MARCH6 Antibody antibody

STJ118550 100 µl
EUR 277

Anti-Anti-MARCH7 Antibody antibody

STJ118752 100 µl
EUR 277

Anti-Anti-SEPT3 Antibody antibody

STJ118990 100 µl
EUR 277

Anti-Anti-SEPT1 antibody antibody

STJ119580 100 µl
EUR 277
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012]

Anti-Anti-SEPT7 Antibody antibody

STJ116214 100 µl
EUR 277
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT8 Antibody antibody

STJ117206 100 µl
EUR 277
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-SEPT12 Antibody antibody

STJ117759 100 µl
EUR 277
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene.

Monoclonal NGF/proNGF Neutralizing Antibody Antibody

AMM06679G 0.05mg
EUR 528
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103034
  • EUR 453.00
  • EUR 133.00
  • EUR 1302.00
  • EUR 620.00
  • EUR 342.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103035
  • EUR 467.00
  • EUR 133.00
  • EUR 1344.00
  • EUR 634.00
  • EUR 342.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103036
  • EUR 481.00
  • EUR 133.00
  • EUR 1414.00
  • EUR 662.00
  • EUR 356.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Hepatitis C Virus Antibody (HCV) Antibody

abx023924-1mg 1 mg
EUR 1205
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319902
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319903
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319904
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319906
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319907
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319908
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319914
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319915
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319916
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319929
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319930
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319931
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody (HRP)

20-abx311666
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody (FITC)

20-abx311667
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Ly1 Antibody Reactive (LYAR) Antibody (Biotin)

20-abx311668
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Anti Deoxyribonucleic Acid Antibody (DNA) Antibody

abx411057-50ug 50 ug
EUR 592
  • Shipped within 1 week.

Anti-Glycoprotein 210 Antibody (gp210) Antibody

abx233571-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Cytokeratin 7 antibody-Cytoskeleton Marker Antibody

48169-100ul 100ul
EUR 333

Cytokeratin 7 antibody-Cytoskeleton Marker Antibody

48169-50ul 50ul
EUR 239

Anti CD22 Antibody: CD22 Monoclonal Antibody

065-A-01mg 0,1 mg
EUR 267.5
  • Category: Antibody, Signal Transduction Antibodies, mAb
Description: anti-CD22 monoclonal antibody

Anti CD22 Antibody: CD22 Monoclonal Antibody

065-A-1000ug 1000 ug
EUR 1282.5
  • Category: Antibody, Signal Transduction Antibodies, mAb
Description: anti-CD22 monoclonal antibody

Antibody Pair to ApoA-V antibody

10R-1876 100 ul
EUR 651
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody

Goat anti- human Antibody^Polyclonal antibody

LSMab09896 100 ug
EUR 438

Anti-Noelin Antibody BIOTIN Antibody BIOTIN

STJ501938 100 µg
EUR 586

Anti-Noelin Antibody FITC Antibody FITC

STJ501939 100 µg
EUR 586

Anti-Noelin Antibody BIOTIN Antibody BIOTIN

STJ501940 100 µg
EUR 586

Anti-Noelin Antibody FITC Antibody FITC

STJ501941 100 µg
EUR 586

Antibody for Human alpha Tubulin Antibody

SPC-692D 0.1mg
EUR 354
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A390 0.1mg
EUR 401
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A488 0.1mg
EUR 400
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A565 0.1mg
EUR 400
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A594 0.1mg
EUR 400
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A633 0.1mg
EUR 400
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A655 0.1mg
EUR 400
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A680 0.1mg
EUR 400
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A700 0.1mg
EUR 400
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700.

Antibody for Human alpha Tubulin Antibody

SPC-692D-ALP 0.1mg
EUR 394
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase.

Antibody for Human alpha Tubulin Antibody

SPC-692D-APC 0.1mg
EUR 399
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC .

[Prevalence and incidence of type 2 diabetes in Iceland 2005-2018]

Introduction: The variety of folks with kind 2 diabetes has elevated in Iceland in the previous couple of a long time. We utilized the nationwide database on prescribed medicine from the Directorate of Well being to estimate the prevalence and incidence of kind 2 diabetes in Iceland and made prediction on the prevalence of kind 2 diabetes in Iceland in 10 and 20 years.

Materials and strategies: Prevalence and incidence of kind 2 diabetes for the interval 2005-2018 was estimated primarily based on prescriptions of diabetes medicine within the nationwide prescription database containing all prescriptions in Iceland through the interval. The consequence was in comparison with the consequence from the REFINE-Reykjavik research (potential, population-based cohort research) from 2004 to 2011 and printed knowledge from the USA from 1980 to 2016.

Outcomes: The prevalence of kind 2 diabetes greater than doubled in close to all age teams in each women and men within the interval 2005-2018. The incidence elevated by 2.8% yearly (in 18-79 years outdated). The variety of folks in Iceland with kind 2 diabetes was 10600 in 2018 and had increased from 4200 within the 12 months 2005. Comparability with the outcomes of the REFINE-Reykjavik research confirmed an underestimation (29% in women and men) of the prevalence of kind 2 diabetes. If the rise in kind 2 diabetes continues at an analogous fee as within the years 2005-2018 the variety of folks with diabetes in Iceland might be close to 24000 within the 12 months 2040.

Conclusion: Linear improve was seen in incidence and prevalence of individuals with kind 2 diabetes within the years 2005-2018. Related evolution was seen in USA from 1984. To be able to counteract the rise of kind 2 diabetes following the identical path as has been seen within the USA, focused measures are wanted.

The Impact of Monetary Incentives on High quality Measures within the Remedy of Diabetes Mellitus: a Randomized Managed Trial

Background: Monetary incentives are sometimes used to enhance high quality of care in continual care sufferers. Nonetheless, the proof in regards to the impact of monetary incentives continues to be inconclusive.

Goal: To check the impact of monetary incentives on high quality measures (QMs) within the remedy of sufferers with diabetes mellitus in main care. We incentivized a scientific QM and a course of QM to check the impact of monetary incentives on various kinds of QMs and to research the spill-over impact on non-incentivized QMs.

Design/members: Parallel cluster randomized managed trial primarily based on digital medical data database involving Swiss normal practitioners (GPs). Practices had been randomly allotted.

Intervention: All members acquired a bimonthly suggestions report. The intervention group moreover acquired potential monetary incentives on GP degree relying on their efficiency.

Fundamental measures: Between-group variations in proportions of sufferers fulfilling incentivized QM (course of QM of annual HbA1c measurement and scientific QM of blood strain degree beneath 140/95 mmHg) after 12 months.

Key outcomes: Seventy-one GPs (median age 52 years, 72% male) from 43 completely different practices and subsequently 3838 sufferers with diabetes mellitus (median age 70 years, 57% male) had been included. Proportions of sufferers with annual HbA1c measurements remained unchanged (intervention group decreased from 79.Zero to 78.3%, management group from 81.5 to 81.0%, OR 1.09, 95% CI 0.90-1.32, p = 0.39). Proportions of sufferers with blood strain beneath 140/95 improved from 49.9 to 52.5% within the intervention group and decreased from 51.2 to 49.0% within the management group (OR 1.16, 95% CI 0.99-1.36, p = 0.06). Proportions of non-incentivized course of QMs elevated considerably within the intervention group.

Conclusion: GP degree monetary incentives didn’t end in extra frequent HbA1c measurements or in improved blood strain management. Curiously, we might verify a spill-over impact on non-incentivized course of QMs. But, the mechanism of spill-over results of monetary incentives is essentially unclear.

 

Glycemic outcomes associated to melancholy in adults with kind 1 diabetes

Glycemic outcomes of adults with kind 1 diabetes could also be affected by melancholy. Our goal was to match outcomes of “depressed” (Affected person Well being Questionnaire-9 ⩾ 10, N = 83) to “not-depressed” matched management (Affected person Well being Questionnaire-2 < 3, N = 166) adults with kind 1 diabetes with goal measures.

The depressed group had poorer blood glucose management and, for these with glucose meter downloads, fewer glucose assessments/day. The teams didn’t differ on glucose variability or episodes of hypoglycemia. Despair in adults with kind 1 diabetes is related to poorer glycemic management and fewer blood glucose monitoring. Future analysis ought to study whether or not remedy of melancholy ends in higher self-care and glycemic outcomes.

 

, , , , , ,

Post navigation

Leave a Reply

Your email address will not be published. Required fields are marked *